LYGEN (chlordiazepoxide hydrochloride) by Teva is clinical pharmacology chlordiazepoxide hcl has antianxiety, sedative, appetite-stimulating and weak analgesic actions. Approved for anxiety disorders, for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism and 3 more indications. First approved in 1976.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Chlordiazepoxide HCl has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The precise mechanism of action is not known. The drug blocks EEG arousal from stimulation of the brain stem reticular formation. It takes several hours for peak blood levels to be…
Worked on LYGEN at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Polygenic Risk Driven Pragmatic Statin Trial for Heart Disease Prevention
Utility and Effectiveness of Polygenic Risk Scoring (PRS) for Coronary Artery Disease (CAD)
Prospective Electronic Polygenic Risk Study - Second Phase
Prospective Electronic Polygenic Risk Study
Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer